GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
BIODEL INC. (BIOD) [hlAlert]

Rating:
Outperform
BIOD
down 99.03 %

BIODEL INC. (BIOD) rated Outperform with price target $32 by Leerink Swann

Posted on: Monday,  Aug 25, 2008  8:25 AM ET by Leerink Swann

Leerink Swann rated Outperform BIODEL INC. (NASDAQ: BIOD) on 08/25/2008, when the stock price was $70.12. Since
then, BIODEL INC. has lost 99.03% as of 12/18/2015's recent price of $0.68.
If you would have followed this Leerink Swann 's recommendation on BIOD, you would have lost 99.03% of your investment in 2671 days.

Biodel Inc. (Biodel) is a development-stage specialty pharmaceutical company located in Danbury, Connecticut. The Company is focused on the development and commercialization of treatments for endocrine disorders, such as diabetes and osteoporosis. The Company develops product candidates by applying its formulation technologies to existing drugs in order to improve their therapeutic results. The Company?s initial development efforts are focused on peptide hormones. The Company?s advanced product candidate, VIAject, has been studied in two pivotal Phase III clinical trials for the treatment of patients with Type 1 and Type 2 diabetes. Earlier stage product candidates include VIAtab, a sublingual tablet formulation of insulin and two preclinical product candidates for the treatment of osteoporosis. The Company has developed all of its product candidates utilizing its VIAdel technology that allows the Company to study the interaction between peptide hormones and small molecules.

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/25/2008 8:25 AM Buy
None
70.12 128.00
as of 12/24/2008
1 Week down  -10.35 %
1 Month up  15.13 %
3 Months up  31.07 %
1 YTD up  4.14 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy